Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients: An update

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 5, 2015, Pages 693-710

  Pana, Zoi Dorothea ^a   Kougia, Victoria ^a   Roilides, Emmanuel ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Aspergillus; Candida; Children; Neonates; Therapy

Indexed keywords

ANTIFUNGAL AGENT; AMPHOTERICIN B; ECHINOCANDIN; PYRROLE DERIVATIVE;

CHILD; CHILDHOOD DISEASE; HUMAN; IMMUNOCOMPROMISED PATIENT; NEWBORN; NEWBORN INFECTION; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; SYSTEMIC MYCOSIS; IMMUNOLOGY; MYCOSES;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; CHILD; ECHINOCANDINS; HUMANS; IMMUNOCOMPROMISED HOST; INFANT, NEWBORN; MYCOSES;

EID: 84924370907     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1013936     Document Type: Review

References (109)

1. Steinbach WJ, Roilides E, Berman D, et al. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J 2012;31(12):1252-7
2. Adams-Chapman I, Bann CM, Das A, et al. Neurodevelopmental outcome of extremely low birth weight infants with candida infection. J Pediatr 2013;163(4):961-7; e3
3. Filioti I, Iosifidis E, Roilides E. Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients. Expert Opin Pharmacother 2008;9(18):3179-96
4. Walsh TJ. Primary cutaneous aspergillosis - an emerging infection among immunocompromised patients. Clin Infect Dis 1998;27(3):453-7
5. Etienne KA, Subudhi CP, Chadwick PR, et al. Investigation of a cluster of cutaneous aspergillosis in a neonatal intensive care unit. J Hosp Infect 2011;79(4):344-8
6. Roilides E. Invasive candidiasis in neonates and children. Early Hum Dev 2011;87(Suppl 1):S75-6
7. Steinbach WJ. Epidemiology of invasive fungal infections in neonates and children. Clin Microbiol Infect 2012;16(9):1321-7
8. Barton M, O'Brien K, Robinson JL, et al. Invasive candidiasis in low birth weight preterm infants: risk factors, clinical course and outcome in a prospective multicenter study of cases and their matched controls. BMC Infect Dis 2014;14:327
9. Blyth CC, Chen SC, Slavin MA, et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009;123(5):1360-8
10. Pammi M, Holland L, Butler G, et al. Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis. Pediatr Infect Dis J 2013;32(5):e206-16
11. Shane AL, Stoll BJ. Neonatal sepsis: progress towards improved outcomes. J Infect 2014;68(Suppl 1):S24-32
12. Zaoutis T. Candidemia in children. Curr Med Res Opin 2010;26(7):1761-8
13. Oeser C, Vergnano S, Naidoo R, et al. Neonatal invasive fungal infection in England 2004-2010. Clin Microbiol Infect 2014;20(9):936-41
14. Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001;345(23):1660-6
15. Farmaki E, Evdoridou J, Pouliou T, et al. Fungal colonization in the neonatal intensive care unit: risk factors, drug susceptibility, and association with invasive fungal infections. Am J Perinatol 2007;24(2):127-35
16. Kaufman DA, Gurka MJ, Hazen KC, et al. Patterns of fungal colonization in preterm infants weighing less than 1000 grams at birth. Pediatr Infect Dis J 2006;25(8):733-7
17. Leibovitz E, Livshiz-Riven I, Borer A, et al. A prospective study of the patterns and dynamics of colonization with candida spp. In very low birth weight neonates. Scand J Infect Dis 2013;45(11):842-8
18. Bendel CM. Colonization and epithelial adhesion in the pathogenesis of neonatal candidiasis. Semin Perinatol 2003;27(5):357-64
19. Lupetti A, Tavanti A, Davini P, et al. Horizontal transmission of Candida parapsilosis candidemia in a neonatal intensive care unit. J Clin Microbiol 2002;40(7):2363-9
20. Aliaga S, Clark RH, Laughon M, et al. Changes in the incidence of candidiasis in neonatal intensive care units. Pediatrics 2014;133(2):236-42
21. Zaoutis TE, Prasad PA, Localio AR, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis 2010;51(5):e38-45
22. Fisher BT, Ross RK, Roilides E, et al. Clinical prediction model for candidemia in pediatric icu patients: Failure to validate. In: IDSA, editor. ID Week 2014; Philadelphia PA, USA; 2014
23. Hope WW, Castagnola E, Groll AH, et al. ESCMID guideline for the diagnosis and management of candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012;18(Suppl 7):38-52
24. Groll AH, Castagnola E, Cesaro S, et al. Fourth european conference on infections in leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 2014;15(8):e327-e40
25. Science M, Robinson PD, MacDonald T, et al. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer 2014;61(3):393-400
26. Dvorak CC, Fisher BT, Sung L, et al. Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data. Pediatr Blood Cancer 2012;59(1):21-6
27. Ben-Ami R, Olshtain-Pops K, Krieger M, et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother 2012;56(5):2518-23
28. Lanternier F, Cypowyj S, Picard C, et al. Primary immunodeficiencies underlying fungal infections. Curr Opin Pediatr 2013;25(6):736-47
29. Hundalani S, Pammi M. Invasive fungal infections in newborns and current management strategies. Expert Rev Anti Infect Ther 2013;11(7):709-21
30. Tiffany KF, Smith PB, Benjamin DK Jr. Neonatal candidiasis: prophylaxis and treatment. Expert Opin Pharmacother 2005;6(10):1647-55
31. Kaufman DA. Challenging issues in neonatal candidiasis. Curr Med Res Opin 2010;26(7):1769-78
32. Kumar S, Bansal A, Chakrabarti A, Singhi S. Evaluation of efficacy of probiotics in prevention of candida colonization in a picu-a randomized controlled trial. Crit Care Med 2013;41(2):565-72
33. Kumar S, Singhi S. Role of probiotics in prevention of Candida infection in critically ill children. Mycoses 2013;56(3):204-11
34. Manzoni P, Stolfi I, Messner H, et al. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics 2012;129(1):116-23
35. Demirel G, Celik IH, Erdeve O, et al. Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants. Eur J Pediatr 2013;172(10):1321-6
36. Srinivasjois R, Rao S, Patole S. Prebiotic supplementation in preterm neonates: updated systematic review and metaanalysis of randomised controlled trials. Clin Nutr 2013;32(6):958-65
37. Manzoni P, Jacqz-Aigrain E, Rizzollo S, et al. Antifungal prophylaxis in neonates. Early Hum Dev 2011;87(Suppl 1):S59-60
38. Healy CM, Campbell JR, Zaccaria E, Baker CJ. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazoleresistant candida species. Pediatrics 2008;121(4):703-10
39. Benjamin DK Jr, Hudak ML, Duara S, et al. Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. Jama 2014;311(17):1742-9
40. Kaufman D, Boyle R, Hazen KC, et al. Twice weekly fluconazole prophylaxis for prevention of invasive candida infection in high-risk infants of < 1000 grams birth weight. J Pediatr 2005;147(2):172-9
41. Ericson J, Manzoni P, Benjamin DK Jr. Old and new: appropriate dosing for neonatal antifungal drugs in the nursery. Early Hum Dev 2013;89(Suppl 1):S25-7
42. Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2013;4:CD003850
43. Kaufman DA, Cuff AL, Wamstad JB, et al. Fluconazole prophylaxis in extremely low birth weight infants and neurodevelopmental outcomes and quality of life at 8 to 10 years of age. J Pediatr 2011;158(5):759-65; e1
44. Aydemir C, Oguz SS, Dizdar EA, et al. Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants. Arch Dis Child Fetal Neonatal Ed 2011;96(3):F164-8
45. Violaris K, Carbone T, Bateman D, et al. Comparison of fluconazole and nystatin oral suspensions for prophylaxis of systemic fungal infection in very low birthweight infants. Am J Perinatol 2010;27(1):73-8
46. Austin N, Darlow BA, McGuire W. Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants. Cochrane Database Syst Rev 2013;3:CD003478
47. Lestner JM, Smith PB, Cohen-Wolkowiez M, et al. Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. Br J Clin Pharmacol 2013;75(6):1381-95
48. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis 2009;48(5):503-35
49. Greenberg RG, Benjamin DK Jr. Neonatal candidiasis: diagnosis, prevention, and treatment. J Infect 2014;69(Suppl 1):S19-22
50. Greenberg RG, Benjamin DK Jr, Gantz MG, et al. Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis. J Pediatr 2012;161(2):264-9; e2
51. Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin b and 5-fluorocytosine in neonates. J Pediatr 1990;116(5):791-7
52. Almirante B, Rodriguez D. Antifungal agents in neonates: issues and recommendations. Paediatr Drugs 2007;9(5):311-21
53. Turkova A, Roilides E, Scharland M. Amphotericin b in neonates: deoxycholate or lipid formulation - what is the right choice? Curr Opin Infect Dis 2011;24(2):163-71
54. Linder N, Klinger G, Shalit I, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin b preparations. J Antimicrob Chemother 2003;52(4):663-7
55. Levy I, Shalit I, Birk E, et al. Candida endocarditis in neonates: report of five cases and review of the literature. Mycoses 2006;49(1):43-8
56. Lopez Sastre JB, Coto Cotallo GD, Fernandez Colomer B. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol 2003;20(3):153-63
57. Cetin H, Yalaz M, Akisu M, et al. The efficacy of two different lipid-based amphotericin b in neonatal candida septicemia. Pediatr Int 2005;47(6):676-80
58. Jeon GW, Koo SH, Lee JH, et al. A comparison of ambisome to amphotericin b for treatment of systemic candidiasis in very low birth weight infants. Yonsei Med J 2007;48(4):619-26
59. Caudle KE, Inger AG, Butler DR, Rogers PD. Echinocandin use in the neonatal intensive care unit. Ann Pharmacother 2012;46(1):108-16
60. Manzoni P, Wu C, Tweddle L, Roilides E. Micafungin in premature and non-premature infants: A systematic review of nine clinical trials. Pediatr Infect Dis J 2014;33(11):e291-8
61. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008;197(1):163-71
62. Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010;54(6):2633-7
63. Warn PA, Livermore J, Howard S, et al. Anidulafungin for neonatal hematogenous candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. Antimicrob Agents Chemother 2012;56(2):708-14
64. Wilke MH. Invasive fungal infections in infants-focus on anidulafungin. Clin Med Insights Pediatr 2013;7:7-11
65. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326(13):845-51
66. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995;171(6):1545-52
67. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96(6):2055-61
68. Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother 1999;43(8):1955-60
69. Watanabe N, Matsumoto K, Kojima S, Kato K. Invasive fungal infections in pediatric patients with hematologic malignancies receiving oral amphotericin b solution and early intravenous administration of fluconazole. J Pediatr Hematol Oncol 2011;33(4):270-5
70. Roman E, Osunkwo I, Militano O, et al. Liposomal amphotericin b prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatr Blood Cancer 2008;50(2):325-30
71. Wolff SN, Fay J, Stevens D, et al. Fluconazole vs low-dose amphotericin b for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the north american marrow transplant group. Bone Marrow Transplant 2000;25(8):853-9
72. Mattiuzzi GN, Estey E, Raad I, et al. Liposomal amphotericin b versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 2003;97(2):450-6
73. Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin b in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006;17(8):1306-12
74. Ethier MC, Science M, Beyene J, et al. Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stemcell transplantation: a systematic review and meta-analysis of randomised controlled trials. Br J Cancer 2012;106(10):1626-37
75. Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005;131(1):22-8
76. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103(4):1527-33
77. Yu DT, Peterson JF, Seger DL, et al. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf 2005;14(11):755-67
78. Pana ZD, Roilides E. Risk of azoleenhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem - new dilemma. Pediatr Blood Cancer 2011;57(1):30-5
79. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010;116(24):5111-18
80. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356(4):335-47
81. Cecinati V, Guastadisegni C, Russo FG, Brescia LP. Antifungal therapy in children: an update. Eur J Pediatr 2013;172(4):437-46
82. Cesaro S, Milano GM, Aversa F. Retrospective survey on the off-label use of posaconazole in pediatric hematology patients. Eur J Clin Microbiol Infect Dis 2011;30(4):595-6
83. Groll AH, Tragiannidis A. Update on antifungal agents for paediatric patients. Clin Microbiol Infect 2010;16(9):1343-53
84. Doring M, Muller C, Johann PD, et al. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis 2012;12:263
85. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39(10):1407-16
86. Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006;50(1):143-7
87. Verweij PE, Warris A, Weemaes CM. Preventing fungal infections in chronic granulomatous disease. N Engl J Med 2003;349(12):1190-1; author reply -1
88. Welzen ME, Bruggemann RJ, Van Den Berg JM, et al. A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease. Pediatr Infect Dis J 2011;30(9):794-7
89. Aguilar C, Malphettes M, Donadieu J, et al. Prevention of infections during primary immune deficiencies. Clin Infect Dis 2014;59(10):1462-70
90. Antachopoulos C. Invasive fungal infections in congenital immunodeficiencies. Clin Microbiol Infect 2010;16(9):1335-42
91. Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin b for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010;29(5):415-20
92. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin b for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351(14):1391-402
93. Kobayashi R, Suzuki N, Yoshida M, et al. Efficacy and safety of micafungin for febrile neutropenia in pediatric patients with hematological malignancies: a multicenter prospective study. J Pediatr Hematol Oncol 2013;35(7):e276-9
94. Yoshikawa K, Nakazawa Y, Katsuyama Y, et al. Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. Infection 2014;42(4):639-47
95. Pana ZD, Vikelouda K, Roilides E. Rare fungal infections in children: an updated review of the literature. Curr Fungal Infect Rep 2014;8:21-36
96. Soltani M, Tobin CM, Bowker KE, et al. Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory. Int J Antimicrob Agents 2006;28(6):574-7
97. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010;50(3):291-322
98. Zaoutis TE, Jafri HS, Huang LM, et al. A prospective, multicenter study of caspofungin for the treatment of documented candida or aspergillus infections in pediatric patients. Pediatrics 2009;123(3):877-84
99. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39(11):1563-71
100. Denning DW, Marr KA, Lau WM, et al. Micafungin (fk463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006;53(5):337-49
101. Benjamin DK Jr, Deville JG, Azie N, et al. Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis. Pediatr Infect Dis J 2013;32(11):e419-25
102. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin b for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008;27(9):820-6
103. Benjamin DK Jr, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006;50(2):632-8
104. Mondal RK, Singhi SC, Chakrabarti A, Jayashree M. Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study. Pediatr Crit Care Med 2004;5(6):561-5
105. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21(3):240-8
106. Lehrnbecher T, Attarbaschi A, Duerken M, et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis 2010;29(8):1043-5
107. Vehreschild JJ, Birtel A, Vehreschild MJ, et al. Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol 2013;39(3):310-24
108. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2013;20(Suppl 3):5-26
109. Krishna G, Sansone-Parsons A, Martinho M, et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007;51(3):812-18